Search clinical trials for: Myrbetriq

Total 55 results

Seoul National University Hospital
Il-Yang Pharm. Co., Ltd.

Not yet recruiting

A Trial Evaluating the Clinical Efficacy and Safety of Hibero SR (Mirabegron) 50 mg and Ditropan (Oxybutynin Chloride) 10 mg in Children Between 5 and 18 Years With Overactive Bladder (OAB)

Overactive Bladder

Korea, Republic of
Cedars-Sinai Medical Center

Recruiting

Using Mirabegron to Increase BP in Patients With POTS (RAISE BP)

Syncope | Postural Orthostatic Tachycardia Syndrome | Chronic Orthostatic Intolerance

United States
The University of Texas Medical Branch, Galveston
National Institute on Aging (NIA)

Recruiting

Comparative Effectiveness of Initial OAB Treatment Options Among Older Women at High Risk of Falls

Urinary Bladder, Overactive | Urinary Incontinence | Accidental Falls

United States
University of California, San Diego

Recruiting

ADRB3 Signaling Pathway in Human Adipose Tissue

Obesity, Prediabetes

United States
Astellas Pharma Global Development, Inc.

Recruiting

A Study of Mirabegron in Young Children With Neurogenic Detrusor Overactivity

Neurogenic Detrusor Overactivity

Philippines, Turkey, Belgium, Denmark
Shachi Tyagi
National Institute on Aging (NIA)

Recruiting

Effect of Behavioral Sleep Intervention on Lower Urinary Tract Symptoms in Older Women (SLAB)

Nocturia | Urgency Urinary Incontinence

United States
Walter Reed National Military Medical Center

Recruiting

Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome

Overactive Bladder Syndrome

United States
Philip Kern
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

Mechanisms for Activation of Beige Adipose Tissue in Humans

PreDiabetes

United States
St. Joseph's Healthcare Hamilton

Not yet recruiting

Efficacy And Safety Of Combination Therapy For Treatment Of Overactive Bladder In Male Patients With Benign Prostatic Hyperplasia.

Overactive Bladder | Benign Prostatic Hyperplasia

Canada
Indiana University
Office of Naval Research (ONR)

Completed

MIrabegron and Physiological Function in Cold Environments

Resting Energy Expenditure | Brown Adipose Tissue | Thermogenesis

United States
Christopher Bell
Indiana University

Active, not recruiting

Does Mirabegron Increase the Body Heat Generated by the Nervous System

Thermoregulation

United States
Baylor Research Institute
The Methodist Hospital Research Institute; International Urogynecological Association

Completed

Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder

Overactive Bladder | Lower Urinary Tract Symptoms | Dementia | Incontinence, Urge

United States
Astellas Pharma Global Development, Inc.

Terminated

A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB) (Dolphin)

Pharmacokinetics of Mirabegron | Overactive Bladder (OAB)

Korea, Republic of, Russian Federation, Turkey
Theodore R. Brown, MD MPH
Astellas Pharma Inc

Completed

Study of Behavioral Modification Program and Mirabegron to Improve Urinary Urgency in Multiple Sclerosis (MIRROR)

Multiple Sclerosis

United States
Indiana University
Office of Naval Research (ONR)

Completed

Mirabegron and Physiological Function in Cold Environments

Resting Energy Expenditure | Brown Adipose Tissue | Thermogenesis

United States
Southern Illinois University
Astellas Scientific & Medical Affairs, Inc.; Sisters of the Third Order of...

Terminated

Myrbetriq™ (Mirabegron) to Reduce Pain and Discomfort Following Ureteral Stent Placement

Pain | Urinary Bladder, Overactive | Lower Urinary Tract Symptoms

United States
Université de Sherbrooke
Laval University

Completed

Activation of Brown Adipose Tissue Metabolism Using Mirabegron (GB9)

Type 2 Diabetes

Canada
Astellas Pharma Europe B.V.

Completed

Open-label Phase 3 Study With Mirabegron in Children From 3 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity (Crocodile)

Neurogenic Detrusor Overactivity

Belgium, Croatia, Turkey, Australia, Denmark, Israel, Jordan, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico, Norway, Philippines, Poland, Romania, Serbia, Slovakia, Taiwan
University Hospitals Cleveland Medical Center

Withdrawn

Comparison of Electroacupuncture to Mirabegron for Treatment of Overactive Bladder

Overactive Bladder

United States
Baylor College of Medicine

Completed

Mirabegron as Medical Expulsive Therapy (MET) for Ureteral Stones and Ureteral Stent Pain

Ureteral Obstruction | Flank Pain

United States
Jean-Luc Balligand
University of Oxford; University of Athens; Cliniques universitaires Saint-Luc-... and other collaborators

Active, not recruiting

Assessment of Efficacy of Mirabegron, a New beta3-adrenergic Receptor in the Prevention of Heart Failure (Beta3_LVH)

Hypertrophy, Left Ventricular

Belgium, France, Germany, Greece, Italy, Poland, Portugal, United Kingdom
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder

Overactive Bladder | Pharmacokinetics of Mirabegron | Neurogenic Detrusor Overactivity

Belgium, Denmark, Norway, Poland, Serbia
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB)

Overactive Bladder | Neurogenic Detrusor Overactivity

Denmark, Poland
The University of Texas Health Science Center at...

Completed

Treatment of Spinal Cord Injury Patients for Neurogenic Bladder: Anticholinergic Agent vs. Mirabegron (SCIMYR)

Cognitive Change | Spinal Cord Injuries | Neurogenic Bladder

United States
Thomas Jefferson University
Astellas Pharma Inc

Terminated

Mirabegron in Achalasia: A Clinical and Manometric Proof of Concept Pilot Study

Achalasia

United States
Astellas Pharma Global Development, Inc.

Completed

Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB) (PILLAR)

Overactive Bladder (OAB)

United States, Canada
Johns Hopkins University
Astellas Pharma US, Inc.

Completed

Mirabegron For Erectile Dysfunction

Overactive Bladder | Urinary Incontinence | Erectile Dysfunction

United States
Loyola University
Astellas Pharma US, Inc.

Completed

Mirabegron and Urinary Urgency Incontinence

Overactive Bladder

United States
State University of New York at Buffalo
Astellas Pharma Inc

Withdrawn

Mirabegron for the Treatment of Pain Motivated Urinary Frequency and Urgency in Women

Urinary Frequency/Urgency | Bladder Pain Syndrome | Bladder Irritable

United States
Genuine Research Center, Egypt
Multi-Apex Pharma

Completed

Bioequivalence Study of Mirabegron From Bladogra 25 mg Extended Release Tablets (Multi-Apex for Pharmaceutical Industries, Egypt) Versus Myrbetriq 25 mg Extended Release Tablets (Marketed by Astellas Pharma US, Inc, Product of Japan)

Healthy

Egypt
Astellas Pharma Global Development, Inc.

Completed

A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH) (PLUS)

Overactive Bladder | Benign Prostatic Hyperplasia

United States, Canada, Czechia, France, Germany, Italy, Poland, Spain, United Kingdom
Astellas Pharma Global Development, Inc.

Completed

A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB) (PREFER)

Overactive Bladder (OAB)

United States, Canada
Philip Kern
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Brown Fat Activation Study

Metabolic Syndrome | Obese

United States
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder (Symphony)

Urologic Diseases | Urinary Bladder, Overactive | Urinary Bladder Diseases | Urological Manifestations | Signs and Symptoms

Belarus, Belgium, Czechia, Denmark, Finland, France, Germany, Hungary, Italy, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Slovakia, Spain, Sweden, Ukraine, United Kingdom
Kessler Foundation
National Institute on Disability, Independent Living, and Rehabilitation...

Unknown

Mirabegron and Oxybutynin Safety and Efficacy Trial in Spinal Cord Injury (MOSET-SCI)

Spinal Cord Injuries | Urinary Bladder, Neurogenic

United States
Philadelphia Urosurgical Associates
Astellas Pharma Global Development, Inc.

Terminated

A Pilot Study of the Effects of Mirabegron on Symptoms in Patients With Interstitial Cystitis (MirabegronIC)

Cystitis, Interstitial

United States
Aaron Cypess
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...

Completed

Effects of b3-Adrenergic Receptor Agonists on Brown Adipose Tissue

Obesity

United States
Southern Illinois University
Astellas Scientific & Medical Affairs, Inc.; Sisters of the Third Order of...

Completed

Myrbetriq™ (Mirabegron) to Improve Disordered Sleep in Subjects With Lower Urinary Tract Symptoms (LUTS)

Lower Urinary Tract Symptoms | Nocturia

United States
HealthPartners Institute

Completed

Mirabegron in Parkinson Disease and Impaired Cognition (MICT-PD)

Overactive Bladder | Parkinson Disease | Impaired Cognition

United States
University of California, San Francisco

Completed

Treatment of Incontinence Without Memory Problems (TRIUMPH)

Urge Incontinence | Urinary Incontinence, Urge

United States
Astellas Pharma Europe Ltd.

Completed

A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice (BELIEVE)

Urologic Diseases | Overactive Bladder | Urinary Bladder Diseases | Urgency Incontinence | Urinary Bladder Overactive

Czechia, Denmark, Greece, Ireland, Slovakia, Spain, Sweden, United Kingdom
Lawson Health Research Institute

Terminated

Urodynamic and Clinical Efficacy of Mirabegron for Neurogenic Bladder Patients

Urinary Bladder, Neurogenic

Canada
Astellas Pharma Europe B.V.

Completed

This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder (SYNERGY)

Overactive Bladder | Urgency Incontinence | Urinary Bladder Overactive | Urinary Bladder Diseases\Urologic Diseases

United States, Argentina, Australia, Belgium, Bulgaria, Canada, China, Colombia, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, Italy, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico, Netherlands and more
Astellas Scientific & Medical Affairs, Inc.

Completed

A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB) (PERSPECTIVE)

Urologic Diseases | Overactive Bladder | Urinary Bladder Diseases | Urinary Bladder Overactive

United States, Canada
Astellas Pharma Europe B.V.

Completed

A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder (SYNERGY II)

Overactive Bladder | Urgency Incontinence | Urinary Bladder Overactive | Urinary Bladder Diseases\Urologic Diseases

Belgium, Russian Federation, Korea, Republic of, United States, Germany, Spain, Australia, Bulgaria, Canada, Czechia, Denmark, Estonia, Finland, Hungary, Italy, Latvia, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Norway, ... and more
Astellas Pharma Europe Ltd.

Completed

A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin) (BESIDE)

Urologic Diseases | Urinary Bladder Diseases | Urinary Bladder Overactive

United States, Armenia, Australia, Austria, Belgium, Canada, Czechia, Denmark, Finland, France, Georgia, Germany, Greece, Hungary, Ireland, Israel, Italy, Lebanon, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Slov... and more
CHU de Quebec-Universite Laval

Completed

Pilot Study of Mirabegron in Pediatric Patients With Overactive Bladder (Mirabegron)

Overactive Bladder | Urinary Incontinence
CHU de Quebec-Universite Laval

Completed

Add-on Mirabegron in Pediatric Patients With Refractory Overactive Bladder (Add-on-Mira)

Overactive Bladder | Urinary Incontinence
Astellas Pharma Europe Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment. (BEYOND)

Urologic Diseases | Urinary Bladder, Overactive | Urinary Bladder Diseases

Greece, Ireland, Armenia, Austria, Belarus, Belgium, Bulgaria, Canada, Czechia, Denmark, Finland, France, Georgia, Germany, Hungary, Italy, Kazakhstan, Latvia, Lebanon, Lithuania, Netherlands, Norway, Poland, Portugal, Russian Federation, Slovaki... and more
Astellas Pharma Inc

Completed

Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (SCORPIO)

Urinary Bladder, Overactive

Australia, Belgium, France, Spain, Sweden, Bulgaria, Romania, Italy, Greece, South Africa, Austria, Poland, United Kingdom, Hungary, Denmark, Netherlands, Switzerland, Ireland, Lithuania, Russian Federation, Germany, Latvia, Slovakia, Finlan... and more

Search clinical trials for: Myrbetriq

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kazakhstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations